Skip to main content
. 2021 Aug 12;12:4906. doi: 10.1038/s41467-021-25103-7

Fig. 6. Gene signatures derived from single-nuclei sequencing and spatial transcriptomics outperforms bulk-RNA sequencing-based consensus classifiers in predicting response to immune checkpoint therapy.

Fig. 6

a Association of snSeq/Visium-derived signature scores, or consensus MIBC subtypes, with RECIST v1.1 response in IMvigor 210 Cohort 2 (N = 298, Fisher exact test). b Flow chart for incorporating a CDH12 score into clinical decision making for treatment-naïve and chemoresistant tumors.